|
|
||||||||
1From the Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri; 2The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and the 3Department of Urology, Northwestern University Medical School, Chicago, Illinois.
PURPOSE. Examine the effect of (pigment epitheliumderived growth factor; PEDF) on laser-induced choroidal neovascularization (CNV).
METHODS. Adult C57Bl/6 mice were anesthetized and four laser spots were placed in each quadrant of the fundus with a krypton red laser (614 nm, 50 µm, 0.05 second, 200 mW). Animals were treated with various doses of PEDF administered with miniosmotic pumps implanted subcutaneously. Seven days after laser treatment, mice were perfused with 3% FITC high-molecular-weight dextran, the eyes enucleated, and neovascularization analyzed by confocal microscopy. Data were recorded as the volume of the neovascular complex. The effect of PEDF on endothelial cell migration, vascular tube formation in synthetic basement membrane, and VEGF production was also determined.
RESULTS. Mice receiving a lower dose of PEDF (90 µg/mL) had significantly decreased areas of CNV. A high dose of PEDF (360 µg/mL) significantly increased CNV, whereas an intermediate dose (180 µg/mL) of PEDF had no effect. PEDF inhibited endothelial cell migration and vascular tube formation at lower doses (0.55 µg/mL). High doses of PEDF (2550 µg/mL) stimulated endothelial cell migration, enhanced vascular tube formation in vitro, and stimulated VEGF production from endothelial cells. Neutralizing anti-VEGF antibody completely reversed the stimulatory effects of high doses of PEDF on CNV in vivo.
CONCLUSIONS. PEDF demonstrates opposing effects on CNV and endothelial cell function. Whereas low doses are inhibitory, high doses can augment the development of the neovasculature. These results suggest that the effects of PEDF on neovascularization are more complex than originally believed and that caution should be exercised when PEDF therapies are considered.
This article has been cited by other articles:
![]() |
M. Campos, J. Amaral, S. P. Becerra, and R. N. Fariss A Novel Imaging Technique for Experimental Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5163 - 5170. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Banin, M. I. Dorrell, E. Aguilar, M. R. Ritter, C. M. Aderman, A. C. H. Smith, J. Friedlander, and M. Friedlander T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of Quantification Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2125 - 2134. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF] |
||||
![]() |
J. Amaral, R. N. Fariss, M. M. Campos, W. G. Robison Jr, H. Kim, R. Lutz, and S. P. Becerra Transscleral-RPE Permeability of PEDF and Ovalbumin Proteins: Implications for Subconjunctival Protein Delivery Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4383 - 4392. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Notari, A. Miller, A. Martinez, J. Amaral, M. Ju, G. Robinson, L. E. H. Smith, and S. P. Becerra Pigment Epithelium-Derived Factor Is a Substrate for Matrix Metalloproteinase Type 2 and Type 9: Implications for Downregulation in Hypoxia Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2736 - 2747. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |